NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

Active Not RecruitingN/A

Sponsor: Pfizer

Conditions: Refractory Multiple Myeloma (RRMM)

Interventions: Non intervention

Countries: Taiwan

The purpose of this study is to evaluate: * What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan? * What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan? * What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

1. Patients age ≥ 18 years at the initiation of elranatamab
2. Patients who have received at least one dose of elranatamab in consistent with the approved label in Taiwan.
3. Evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. The ICD waiver is acceptable for patient who was ceased before recruitment.

Exclusion criteria:

Patients who participated in any prior clinical trials using elranatamab.

Locations (4)

Kachsiung, Taiwan
Taichung, Taiwan
Taipei, Taiwan
Taoyuan, Taiwan